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Abstract Urocortin-1 (UCN) a corticotropin releasing-
factor (CRF)relatedpeptide, hasbeen foundtobe expressed
in many different tissues like the central nervous system, the
cardiovascular system, adipose tissue, and skeletal muscle.
The effects of UCN are mediated via stimulation of CRF-
receptors 1 and 2 (CRFR1 and 2, CRFR’s) with a high
afﬁnity for CRFR2. It has been shown that the CRF-related
peptidesandCRFR’sareinvolvedintheregulationofstress-
related endocrine, autonomic and behavioural responses.
Using immunocytochemistry, immunohistochemistry and
RT–PCR, we now can show the differentiation dependent
expression of UCN mRNA and peptide in human mesen-
chymal progenitor cells (MSCs) directed to the osteoblastic
phenotype for the ﬁrst time. UCN expression was down
regulated by TGF-beta and BMP-2 in the early proliferation
phase of osteoblast development, whereas dexamethasone
(dex) minimally induced UCN gene expression during
matrix maturation after 24 h stimulation. Stimulation of
MSCs for 28 days with ascorbate/beta-glycerophosphate
(asc/bGp) induced UCN gene expression at day 14. This
effect was prevented when using 1,25-vitamin D3 or dex in
addition. There was no obvious correlation to osteocalcin
(OCN) gene expression in these experiments. In MSCs from
patients with metabolic bone disease (n = 9) UCN gene
expressionwassigniﬁcantlyhighercomparedtoMSCsfrom
normal controls (n = 6). Human MSCs did not express any
of the CRFR’s during differentiation to osteoblasts. Our
results indicate that UCN is produced during the develop-
ment of MSCs to osteoblasts and differentially regulated
during culture as well as by differentiation factors. The
expression is maximal between proliferation and matrix
maturationphase.However,UCNdoesnotseemtoactonthe
osteoblastitselfasshownbythemissingCRFR’s.Ourresults
suggest new perspectives on the role of urocortin in human
skeletal tissue in health and disease.
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Introduction
Urocortin 1 (UCN) was initially described by Vaughan
et al. (1995) in the rat midbrain. UCN is a 40 amino acid
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DOI 10.1007/s10735-009-9244-zpeptide related to the hypothalamic hormone corticotropin-
releasing factor (CRF). The UCN peptide is 63% identical
to ﬁsh urotensin and 45% identical to mammalian CRF
(Latchman 2002). The effects of UCN and CRF are med-
iated by binding to two distinct receptors, CRFR1 and
CRFR2 (Latchman 2002).
Urocortin and its related peptides such as UCN II and III
are members of the corticotropin-releasing hormone (CRH)
system, with a widespread tissue distribution (Bamberger
et al. 2007; Boorse and Denver 2006; Sehringer et al.
2004). They are known to be relevant molecules in the
management of many organ conditions and seem to play
diverse roles in physiology, development and behavior in
vertebrates, including suppression of appetite, regulation of
anxiety, enhancement of cardiac contractility, antihypo-
trophic effects on skeletal muscle, vasodilatation, temper-
ature regulation and neoangiogenesis (Boorse and Denver
2006; Latchman 2002; Vaughan et al. 1995). Many studies
have shown the relevant effects of CRF-related peptides
such as UCN in stress responses. One of the interesting
aspects of UCN function is its role in the regulation of
neuropeptide Y (NPY) and leptin in adipose tissue and
energy balance (Fekete et al. 2002). Besides their expres-
sion in brain, UCN and the CRFRs have been identiﬁed at
multiple peripheral sites. UCN-related peptides seem to be
relevant in the pathogenesis of diverse conditions, e.g.,
hypertension, congestive heart failure, rheumatoid arthritis,
food intake, spontaneous abortion and atopic/allergic dis-
orders (Bale et al. 2004; Fekete and Zorrilla 2007).
Recently, possible effects of UCN were reported on pro-
liferation during cell growth, differentiation, cell repair,
apoptosis and cancer (Ikeda et al. 2002; Slominski et al.
2006).
The expression of genes and proteins during osteoblast
development and transcriptional regulation of these genes
is of essential importance in the regulation of osteoblast
differentiation and function (Hughes et al. 2006). In this
study, we investigated UCN expression at the mRNA and
peptide levels, in addition to the expression of CRFRs,
during osteoblastic differentiation of mesenchymal pro-
genitor cells and examined possible regulatory effects of
growth factors on UCN gene expression.
Materials and methods
Cell culture
Bone specimens were obtained from the iliac crest of 5
patients (4 women, 1 man; age 36.2 ± 5.2 years) under-
going corrective surgery after traumatic fracture. None of
the patients had signs or symptoms of bone or autoim-
mune diseases. The study was approved by the
Institutional Review Board of the University of Goettin-
gen. Following written informed consent, we obtained
RNA from both primary and second passage mesenchymal
progenitor cells from cultures of trabecular bone explants
as previously described (Siggelkow et al. 1999). Addi-
tional experiments revealed the mesenchymal origin of the
cells. When stimulated accordingly, the cells differentiated
into adipocytes, chondrocytes and osteoblasts. With FACS
analysis of surface antigens, the cells showed a proﬁle
consistent with a mesenchymal origin (mean ± SD of
three donors): CD45: 4.7 ± 2.9%, CD34: 4.0 ± 2.6%
(hematopoietic origin) CD44: 10.6 ± 4.8%, CD90:
93.7 ± 5.6%, CD105: 34.9 ± 20.2% (mesenchymal stem
cell markers) (Ponce et al. 2008). Therefore, the cells
formerly referred to as preosteoblasts were multipotent
and were thus termed mesenchymal progenitor cells or
trabecular bone-derived mesenchymal stem cells (MSCs)
(Ponce et al. 2008).
MSCs were grown out of explants, maintained in med-
ium (DMEM with 10% fetal calf serum (FCS), glutamine
(58.5 lg/ml), penicillin (100 U/ml), and streptomycin
(100 lg/ml)), at 37C in a humidiﬁed 95% air/5% CO2
atmosphere described as basal conditions as from now.
Cultures were initiated within 3 hours of receiving the bone
chips and fed twice a week. Initial assessment of UCN
expression was performed under established culture stim-
ulation with beta-glycerophosphate (bGp, 10 mM, Sigma,
Taufkirchen, Germany) and ascorbate (asc, 50 lg/ml,
sigma, Taufkirchen, Germany). Differentiation-dependent
gene expression was investigated in a human model of
osteoblast differentiation initially described for rat osteo-
blasts by Owen and colleagues (Owen et al. 1990) and
conﬁrmed by us in the human model using stimulation with
an identical concentration of bGp and asc in addition to
dexamethasone (dex, 10
-8 M, Sigma, Taufkirchen, Ger-
many) (Siggelkow et al. 2004). For this experiment cell
conﬂuence of ﬁrst passage cells plated at a density of
2 9 10
5 cells per well was reached between days 10 and 12
when the experiment started. Day 28 in culture therefore
represents day 28 after conﬂuence. The differentiation
sequence in this model is characterized by the three phases,
proliferation, matrix maturation and mineralization (Owen
et al. 1990). In addition we analyzed UCN gene expression
during 28 days in MSCs stimulated beginning at conﬂu-
ence with control compared to asc in combination with
bGp, asc in combination with bGp and 1,25-vitamin D3
(5 9 10
-8 M), furthermore asc, bGp and dex using the
former concentrations and ﬁnally all four components
combined. To obtain a sufﬁcient number of cells for this
experiment, cells of third passage were used. Cells were
plated at 10
5 cells/well, grown until conﬂuence with 10%
FCS, switched to 1% human serum for 3 days when the
experiment started for 28 days.
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different growth factors on UCN expression using standard
concentrations of differentiating agents. MSCs in the sec-
ond passage were cultured for 28 days using basal condi-
tions without any differentiation factors. Cells therefore
represent MSCs not directed to the osteoblastic phenotype
(Siggelkow et al. 1999). For the ﬁnal 24 hours, the different
factors were added separately to the medium in comparison
to 0.1% BSA and solvent. For this experiment, BMP-2
(50 ng/ml, PromoCell, Heidelberg), TGF-beta (1 ng/ml,
PromoCell, Heidelberg), and dex (10
-8 M) were used for
24 h on days 4, 14 and 28.
Real-time PCR
Real-time PCR was performed using a Mastercycler
Eppendorf Realplex
2 detection system with Mastercycler
ep gradients software. Reactions were set up in 96-well
plates using the following concentrations: 0.2 lM of each
sense and antisense primer for target genes (see below),
4.5 ll Platinum Sybr Green qPCP superMix-UDP (Invit-
rogen) and 1 ll cDNA I (250 ng mRNA) in a 10 ll reac-
tion volume. A two-step ampliﬁcation protocol was chosen,
with initial denaturation at 95C for 2 min, followed by
40 cycles with 15 s denaturation at 95C, 15 s annealing at
60C and 20 s extension at 68C. Finally, a dissociation
protocol was performed to control for speciﬁcity of
ampliﬁcation products. For time course expression, the
amount of PCR product was measured relative to the
expression of the housekeeping gene EEF1A1 [house-
keeping genes, as previously described (Siggelkow et al.
1999, 2004)] analyzed by the threshold-cycle (Ct) method.
The speciﬁcity of PCR products was conﬁrmed by
sequencing (Seqlab, Goettingen. Germany). The same
procedure was used to detect the CRFR’s (1 and 2) mRNA
with known sense and antisense primers as previously
described (Kimura et al. 2002; Nazarloo et al. 2006; Seh-
ringer et al. 2004; Tezval et al. 2009b; Table 1).
Preparation for immunocytochemical (ICC)
and immunohistochemistry staining
TheinitialstepoftheICCprocedureinvolvedpreabsorption
of the eight-chamber tissue culture slides with FCS free of
gammaglobulin(GG-free)(45 min,RT).Thiswasfollowed
by incubations with the ﬁrst (1:50, 1:100) and then the
secondantibody(1:50)(eachfor60 min,RT).Thelatterwas
conjugated with FITC and pre absorbed (60 min, RT) with
human sera. The cells were mounted with Fluoromount
(Southern Biotechnology, Birmingham, England)/1,4-
diazabicyclo-2.2.2.-octane(DABCO)(200 mg/ml)(Aldrich
Chemicals,Steinheim,Germany).Resultsweredocumented
on Ectachrome Elite 400 (Eastman Kodak, Rochester, NY,
U.S.A.) using the immunoﬂuorescence microscope Ortho-
plan (ﬁlter L3 533670, objectives: NPL Fluostar 40/1.30 oil
and 170/2 10/0.45 oil) (Leitz, Wetzlar).
The immunoﬂuorescence analysis with 40,6-Diamidino-
2-phenylindol staining (DAPI) were carried out as previ-
ously described for UCN expression in MSCs stimulated to
the osteoblastic phenotype with bGp, asc and dex (Tezval
et al. 2009a).
Renal tissue was selected for immunohistochemical
staining. The tissue was ﬁxed in 4% buffered formalin and
embedded in parafﬁn. Serial sections of 5 lm were cut
from parafﬁn blocks, mounted on APES-coated slides,
deparafﬁnized in xylene and rehydrated in graded alcohol
to PBS (50 mM Tris, 150 mM NaCl, pH 7.4). The slides
were microwaved for 4 9 3 min in 10 mM citrate, pH 6.0.
After cooling, slides were washed in PBS, blocked for
30 min at room temperature with normal goat serum and
incubated with Anti-UCN serum (Abcam). Immunoreac-
tivity was detected with the standard ABC protocol. For
negative controls, the same procedures were done in
absence of primary antibody. Moreover, incubation of
synthetic UCN with an antibody against UCN abolished the
observed signals and demonstrated the speciﬁcity of the
documented immunoreactivity for UCN. Renal tissue was
used as positive control because of known expression of
UCN (Tezval et al. 2009a). The stained renal tissue was
analyzed using confocal microscopy (for better analysis of
stained proximal tubuli).
Analysis of MSCs from patients with metabolic bone
diseases
We studied MSCs from nine patients aged 24–73 years
(median age 55 years, mean 52.4 ± 15.4 years; ﬁve male,
four female) with metabolic bone diseases of different
origins who had been referred for bone biopsy, as pub-
lished previously (Siggelkow et al. 2003). All patients had
a preliminary diagnosis of either osteopenia (3 patients) or
osteoporosis (6 patients.) according to WHO criteria. All
patients gave informed consent and the study was approved
by the ethics committee of Goettingen University Medical
Center. Bone biopsies from the iliac crest were divided into
two parts; one was used for histomorphometric evaluation
and the other for initiation of MSC cultures as described
(Siggelkow et al. 2003, 2004). The ﬁnal diagnosis based on
histomorphometry, were primary osteoporosis of varying
severity (n = 5), steroid osteoporosis (n = 1) and mild
intestinal osteopathy (n = 3) (Siggelkow et al. 2003).
We also studied primary MSC cultures from six subjects
who underwent operations due to trauma or plastic surgery
without evidence of any bone or joint disease (mean age
58 ± 12.7 years). Bone material was taken either from the
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123iliac crest or from the tibia plateau. Cells from bone dis-
eased patients and these healthy controls were grown to
near conﬂuence using highly standardised conditions and
fed twice a week. Cells were also fed 24 h before analysis.
After 5 to 6 weeks (39 ± 7.7 days), primary culture cells
were harvested with guanidine isothiocyanate for mRNA
analysis.
Statistical analysis
Statistical analysis of control and stimulated levels was
performed with the Kruskal–Wallis test for signiﬁcance
between all groups. P\0.05 was considered signiﬁcant
(GraphPad Prism version 3.0).
Results
In this work, we investigated the developmental, gene and
peptide expression of UCN. Apart from the inﬂuence of
time, we examined several cofactors known to play
important roles during osteoblast differentiation.
Tissue speciﬁc gene expression
Using reverse transcriptase PCR analysis we showed the
UCN gene expression in MSCs after incubation with bGp
and asc. Human heart cells served as positive control due to
the known high expression of UCN (Fig. 1). The analyzed
cells were from day 39 of MSC culture.
Detection of CRFRs
As shown in the Fig. 1, we did not ﬁnd any CRFRs in the
osteoblast culture. As positive control we used heart tissue
with known expression of CRFR1 and CRFR2. The
detection of the CRFRs was performed under the same
conditions and cultures used for the investigation of UCN
expression (as described above).
Expression of UCN mRNA by MSCs directed to the
osteoblastic phenotype
We could show time- and stimulation-dependent expres-
sion of UCN mRNA in cell culture directed to an osteo-
blastic phenotype (Fig. 2a). UCN gene expression
increased by 2 fold to its maximum at day 14 during the
matrix maturation stage according to the differentiation
model (Fig. 2b) described by Owen et al. and Siggelkow
et al. (Owen et al. 1990; Siggelkow et al. 1999) after
stimulation with bGp/asc/dex (P\0.05). The decrease in
expression during the mineralization phase was not sig-
niﬁcant (Fig 2a). To further investigate the inﬂuence of
osteogenic differentiation on UCN gene expression we
investigated UCN expression in an experiment with four
different media (Fig. 3). Using only basal conditions there
was no increase in osteogenic differentiation as shown by
basal osteocalcin (OCN) levels, a characteristic marker of
the late osteoblastic phenotype (Fig. 3e–h, open circle).
When asc and bGp were added, OCN gene expression
increased to 1.5 fold levels (Fig. 3e, ﬁlled square). This
only slight increase in osteoblastic phenotype paralleled a
3 fold increase of UCN expression as early as day 7 in
culture, with a decrease to basal levels thereafter besides
increasing osteoblastic phenotype (Fig. 3a, ﬁlled square).
This increase was still detectable when 1,25-vitamin D3
was added in addition but the variation was higher
(Fig. 3b, ﬁlled square). When dex was added the increase
was not detectable any more (Fig. 3c, ﬁlled square), UCN
expression even decreased to nearly 50% from day 0 to
day 7, an effect even stronger when asc, bGp, 1,25-vitamin
Table 1 Primers used for RT–
PCR analysis
Genes Primer bp References
UCN Sense: 50-CGAGCAGAACCGCATCATATT-30 123 Bamberger et al. (2007)
Antisense: 50-ACAGTGCCCTGGTGGCTCT-30
CRFR1 Sense: 50-CAACAATGGCTACCGGGAG-30 66 Sehringer et al. (2004)
Antisense: 50-ACACCCCAGCCAATGCAGA-30
CRFR 2 Sense: 50-GTACAGGAAGGCAGTGAAG-30 66 Sehringer et al. (2004)
Antisense: 50-AAGACAGACACGAAGAAACC-30
OCN Sense: 50-CATGAGAGCCCTCACA-30 310 Ponce et al. (2008)
Antisense: 50-AGAGCGACACCCTAGAC-30
Beta-actin Sense: 50-CTGGAACGGTGAAGGTGACG-30 70 Ponce et al. (2008)
Antisense: 50- AGTCCTCGGCCACATTGTGA-30
EEF1A1 Sense: 50-AGGTGATTATCCTGAACCATCC-30 234 Ponce et al. (2008)
Antisense: 50-AAAGGTGGATAGTCTGAGAAGC-30
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123D3 and dex were added without any difference compared
with control conditions (Fig 3d, ﬁlled square). These
results show an increase of UCN using bGp and asc and a
decrease when osteoblastic differentiation proceeded.
However, UCN gene expression did not correlate with
OCN, which was stimulated 500 fold by the addition of
1,25-vitamin D3 and 2,000 fold after 28 days in culture
proving the osteoblastic phenotype (Fig. 3F, ﬁlled square).
Using dex in addition to asc and bGp decreased OCN gene
expression levels to 24% already at day 7 in culture
(Fig. 3g, ﬁlled square). Dex in addition to 1,25-vitamin
D3 prevents the ﬁnal increase in OCN expression (Fig 3h,
ﬁlled square).
Also, in mesenchymal progenitor cells grown for
28 days without any osteoblastic stimulation, expression of
UCN decreased to about 15% from day 4 to day 28 (Fig. 5,
left column, co day 4, co day 14, co day 28). Because these
cells were not stimulated to the osteoblastic phenotype the
spontaneous differentiation of these cells coincide with a
decrease in UCN expression.
Immunocytochemistry and immunoﬂuorescence
analysis
After 4, 14 and 28 days, we labeled the cells in culture
immunocytochemically (ﬂuorescence microscopy for
cells from day 14 and 28). The cells in culture stained
positive for UCN with low intensity in the cytosolic area
in both immunostaining tests. The staining intensity
decreased from day 14 to day 28 in parallel to UCN
Fig. 1 Gene expression of
UCN by PCR in human
mesenchymal progenitor cells
(MSCs) directed to the
osteoblastic phenotype after
incubation with bGp/asc (upper
picture). Under the same culture
conditions the MSCs die not
express any CRFRs. Human
heart cells were used as positive
control, because of known
expression of UCN and CRFRs
(lower picture)
Fig. 2 a Gene expression of UCN in primary human osteoblasts after
incubation at conﬂuence with bGp/asc/dex (* P\0.05 vs. day 4, 7
and 28). Mean ± SEM (n = 5) analysed by RT–PCR, as described in
methods. b A comparison between the differentiation model as
proposed by Owen in rat osteoblasts and conﬁrmed by Siggelkow in
the human system and UCN gene expression after stimulation with
bGp/asc/dex shows that the maximum of these expression occurred in
the matrix maturation stage. It is important to mention that this is a
schematic comparison for better understanding the differentiation
phase of urocortin-expression
J Mol Hist (2009) 40:331–341 335
123gene expression (Fig 4a–i). Nonspeciﬁc staining was
excluded by omission of the primary antibody. Interest-
ingly, UCN showed an inhomogeneous nuclear staining
with differing intensities in some cells after DAPI
staining (Fig 4e, h). As a further positive control we
stained the renal tissue (immunohistochemistry) with
Fig. 3 Gene expression by real-
time PCR of urocortin (UCN,
a–d) and osteocalcin (OCN,
e–h) in MSCs stimulated for
28 days beginning 3 days after
conﬂuence. Control cells were
fed with 1% human serum. For
stimulation ascorbate (asc) and
beta-glycerophoshate (bGp)
were used either alone (a, e), or
in combination with 1,25-
vitamin D3 (D3, b, f)o r
dexamethasone (dex, c, g)o rD 3
and dex (d, h). UCN and OCN
are depicted relative to the
housekeeping gene beta-actin.
Values at day 0 were arbitrarily
put to 1, therefore the presented
data show relative changes in
gene expression. Differences
between control and stimulated
cultures were analysed by
Kruskal–Wallis test
(* P\0.05, ** P\0.01)
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123known high expression of UCN in proximal tubuli
(Fig 4j–l).
Inﬂuence of growth factors on UCN expression
We investigated the possible regulatory effects of different
growth factors on UCN expression by adding these factors
separately to the medium. This is a relative artiﬁcial situ-
ation, because cells were not stimulated osteogenically
before treatment and in a normal environment all factors
would act in common. But this experiment can reveal the
short time effect of single factors. The results of this
experiment are shown in Fig 5.
To assess the effects of TGF-beta (1 ng/ml), BMP-2
(50 ng/ml), and dex (10
-8 M) on UCN mRNA expres-
sion, we treated MSCs with either vehicle (0.1% BSA
with 0.001% ethanol as solvent) or agent in time course
experiments. Both, BMP-2 and TGF-beta resulted in
signiﬁcant (P\0.005) down regulation of UCN mRNA
on day 4 of culture. TGF-beta led to an initial decrease of
approximately 76% of UCN mRNA on day 4. UCN gene
expression was about 85% suppressed by BMP-2 after
4 days. After 14 days, the effects by BMP-2 and TGF-
beta were weaker, and no signiﬁcant effect of these
growth factors was detectable at day 28. In contrast, dex
treatment had no effect on UCN expression on day 4 but
resulted in a signiﬁcant increase in UCN expression later
in culture (14 and 28 days). These results show a time
dependent expression of UCN in MSCs and in addition, a
differential regulation by growth factors. The UCN
expression was sensitive to TGF-beta and BMP-2 early in
culture and responsive to dex later in differentiation,
however with a reciprocal effect on UCN expression in
MSCs.
Fig. 4 Immunocytochemistry, immunoﬂuorecsence and DAPI stain-
ing (4009 magniﬁcation). Osteoblasts in the cell culture stained
positive for UCN after stimulation with bGp/asc/dex. a Control cells
(unstained), b Immunocytochemically stained cells for UCN (day 4).
c The arrows show the stained cytoplasma of cells in the same
culture. d, g UCN shows a cytoplasmic staining in the immunoﬂu-
orecsence (IF) analysis (D = day 14, G = day 28). e, h Interestingly,
UCN shows also an inhomogeneous nuclear staining with differing
intensities in some cells (DAPI staining, E = day 14, H = day 28).
Bars = 27 lm. F, I: To proof the speciﬁcity of this ﬁnding, the anti-
UCN antibodies were incubated over-night with synthetic human
UCN prior to application in IF (F = day 14, I = day 28). This pre-
treatment completely eliminated the UCN signal, conﬁrming the
speciﬁcity of our UCN detection method. j–l Renal proximal tubuli
were stained for UCN as positive controls (confocal microscopy)
J Mol Hist (2009) 40:331–341 337
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with metabolic bone diseases compared to controls
There was signiﬁcant 2.3 fold higher UCN gene expression
in patients with osteopenia or osteoporosis compared to
control patients as revealed by RT–PCR (Fig 6).
Discussion
Urocortin1 (UCN) is a member of the corticotropin-
releasing hormone (CRH)-related peptides family and is
found in many peripheral tissues and cells. This peptide
seems to have several effects in different tissues (Slominski
and Wortsman 2000). UCN has been reported to have
signiﬁcant effects on cell differentiation and may play a
role in cell proliferation, differentiation and apoptosis via
receptor-mediated (CRFR1, CRFR2) actions in several
organ systems such as the CNS, heart, skeletal muscle,
bowel, uterus, skin and adipose tissue (Carlson et al. 2001;
Ikeda et al. 2002; Slominski et al. 2006).
Bone cells constantly receive signals from surrounding
cells and tissues, and also from distant organs, e.g., via
hormones and growth factors, that regulate their prolifer-
ation, activity and survival (Xing and Boyce 2005).
Understanding the mechanisms and regulation of mesen-
chymal cell proliferation, differentiation towards the
osteoblastic phenotype, and apoptosis will enhance our
knowledge of bone cell function and help us to develop
better therapeutics for the treatment and management of
bone diseases.
With the present study, we demonstrate for the ﬁrst time
that UCN mRNA and protein are expressed by MSCs
directed to the osteoblastic phenotype. The absolute level
of expression was donor-dependent. The differentiation-
and time-dependent expression and regulation by growth
factors conﬁrm the functional relevance of UCN in bone.
Interestingly in some cells in culture, UCN showed not
only a cytoplasmic but also a nuclear positive staining with
differing intensities. As a 40 amino acid peptide, it is likely
that UCN can passively pass the nuclear envelope and
pores, and this may even apply to the UCN precursor
(26 kD). Open questions include whether there is a yet
unidentiﬁed carrier protein involved in an active transport
of UCN into the nucleus and which function can here result
(Tezval et al. 2009a). It is here important to mention, that
the low gene expression of UCN does not correlate or
correspond necessarily with protein expression. It is well
possible that the protein expression is different during
further differentiation and proliferation. Future investiga-
tions are needed to determine such changes and correla-
tions between gene and protein expression of UCN.
According to the model of developmental stages of
osteoblast differentiation ﬁrst described by Owen et al.
(Owen et al. 1990), we saw UCN expression mainly during
the proliferation and matrix maturation stages. UCN
expression was dependent on the differentiation stage of
the osteoblast, with decreasing levels with increasing OCN
expression. To our surprise asc in combination with bGp
was a potent inducer of UCN gene expression. bGP is used
in osteoblastic stimulation as a phosphate donor to induce
Fig. 5 Gene expression of UCN in MSCs after 24 h incubation on
day 4, day 14 and day 28 with single osteogenic factors [TGF-beta-1
(1 ng/ml), BMP-2 (50 ng/ml), or dexamethasone (dex) (10
-8 M)]
compared to control (0.1% BSA with solvent). Mean ± SEM (n = 4)
analyzed by RT–PCR, as described in methods. Values were
normalized to the housekeeping gene EEF1A1 and presented as
percentage of the maximum expression of each gene. a—P\0.01,
b—P\0.05 and c—P\0.01 versus control are signiﬁcant as
calculated by Kruskal–Wallis-test. There is a decrease in basal
expression of UCN from day 4 to day 28 (white bar). At day 4 the
inhibition of UCN expression by TGF-beta and BMP-2 is highly
signiﬁcant, the effect is less on day 14 and not detectable late in
culture. In contrast, dex had no effect early at day 4, but an increase
beginning at day 14 with the maximum effect on day 28
Fig. 6 Real-time PCR measuring the expression of UCN in relation
to a housekeeping gene (beta-actin) in primary cultures of MSCs
established from patients with metabolic bone diseases (n = 9) and
healthy controls (n = 6), grown under standard conditions without
differentiation factors. Differences between the two groups were
analysed by Kruskal–Wallis test (* P\0.05)
338 J Mol Hist (2009) 40:331–341
123mineralization. We showed a dose dependent increase in
OCN expression using concentration between 2.5 and
20 mM (Siggelkow et al. 1999, 2004). Asc is essential for
the secretion of collagen from the osteoblastic cells and,
therefore, is the main inducer of matrix synthesis as a
prerequisite for mineralization (Siggelkow et al. 1999,
2004). These results, at least the gene expression data,
would attribute to UCN a role at the beginning or during
matrix synthesis of osteoblastic cells.
Because cytokines and growth factors signiﬁcantly
inﬂuence the proliferation and differentiation properties of
bone cells, we previously studied Cbfa1/Runx2 and OCN
as target genes for regulation by TGF-beta, BMP-2 and dex
(Viereck et al. 2002). Because of their known expression
behavior after stimulation with different growth factors, a
comparison between these known markers and UCN
expression provided a better understanding of the UCN
expression time course in MSC culture. During the early
stages of bone formation, the role of TGF-beta is to recruit
and stimulate osteoprogenitor cells to proliferate, providing
a pool of early osteoblasts (Hughes et al. 2006). BMP-2 has
a key role during osteoblast commitment and differentia-
tion, but it also seems to regulate the terminal differentia-
tion and mineralization phases and up regulate the
expression of OCN (Rickard et al. 1994). TGF-beta sup-
pressed adipogenic differentiation of MSCs whereas BMP-
2 promoted the osteoblastic and adipogenic phenotype in
parallel (Ponce et al. 2008). During the early phase of
osteoblast differentiation, BMP-2 suppressed OCN
(Viereck et al. 2002), suggesting a possible induction of
proliferation. In our work TGF-beta and BMP-2, besides
their differential effect on the osteoblastic phenotype, both
decreased UCN gene expression early in culture beginning
at day 4. The effect was still evident at day 7 but with lower
levels of basic expression at day 14 the effect could no
longer be detected. Hence, from these data the induction of
proliferation seems to be accompanied by a decrease in
UCN expression. This would suggest for UCN a role after
proliferation in the more differentiated osteoblast. This
interpretation is supported by our results using asc and bGp
showing a role in the matrix maturation phase. In addition,
our immunocytochemical results suggested a time-depen-
dent decrease in UCN peptide induced by TGF-beta, BMP-
2 and dex late in culture using identical conditions (Viereck
et al. 2002), whereas UCN expression was decreased early
in culture by TGF-beta and BMP-2. In addition, UCN gene
expression was increased by short time incubation with dex
alone late in culture. The reciprocal inﬂuence of these
important factors, which regulate bone cell differentiation
and development, also suggests a role for UCN in bone.
To further strengthen our hypothesis we investigated
UCN gene expression in MSC cultures derived from
patients and compared them to those from healthy controls.
The expression in MSCs from patients with metabolic bone
diseases was signiﬁcantly higher. MSCs derived from
patients reﬂect different properties of the original cells in
the patients, shown for proliferation, osteoblast formation
and activity (Marie et al. 1989, 1993). Hence, the higher
UCN expression in patients with metabolic bone diseases
could possibly be regarded as a change in osteoblastic
function further supporting a role for UCN in bone.
It is known that the UCN gene and peptide are able to
inﬂuence skeletal muscle, the vascular system, and fat
tissue and are also involved in stress responses and food
intake. This inﬂuence is in part due to vasodilatation, an
antihypotrophic effect on skeletal muscle, insulin and
temperature regulation in skeletal muscle, energy balance
and many other effects mainly via the CRFR2 receptor
(Bale et al. 2002; Hinkle et al. 2004; Isfort et al. 2005).
Interestingly, Kotz et al. (2002) used a rat model to show
that UCN in the hypothalamic paraventricular nucleus
(PVN) was able to increase leptin and affected uncoupling
poteins-1 and -3. The ﬁndings of Bouxsein et al. could also
suggest a positive effect of weight and leptin on bone turn
over and cortical bone structure in mouse (Bouxsein et al.
2009; Caetano-Lopes et al. 2007). Therefore an interaction
between UCN and leptin concerning an effect on bone
formation and resorption is quite possible. No information
exists on similar effects of UCN in the human system.
We did not ﬁnd any CRFRs during osteoblast differen-
tiation under the conditions used in our study. We assume
that UCN does not have an autocrine function, but instead
has a paracrine or endocrine function in this system. There
might be a possible interaction between UCN expression in
bone cells and adjacent tissues known to express CRF-
receptors such as bone marrow (e.g., monocyte-macro-
phage system and mast cells), muscle, the vascular system
and fat tissue. During osteoblast proliferation and/or dif-
ferentiation, UCN might act in a paracrine and/or endo-
crine manner. Kageyama et al. previously found that both
UCN and UCN 2 induced the accumulation of intracellular
cAMP via CRFR2 binding and signiﬁcantly increased IL-6
secretion by aortic smooth muscle cells (Kageyama et al.
2006), suggesting an important effect on vascular system
and inﬂammation. IL-6 is a known pleiotropic cytokine
with variety of biological activities and proinﬂammatory
effects.
Conclusion
In summary, we found differentiation- and time dependent
expression of UCN mRNA and detected its peptide in
MSCs directed to the osteoblastic phenotype. Furthermore,
UCN gene expression was regulated by important growth
factors. With regard to the known effects of UCN on cell
J Mol Hist (2009) 40:331–341 339
123differentiation and proliferation in other tissues, it can be
speculated that UCN may also play an important role in the
interaction between bone, central nervous system and
surrounding tissues such as bone marrow, fat and the
vascular system.
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